BackgroundFamilial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease characterised with fever, recurrent episodes of self-limiting polyserositis and arthritis. FMF arthritis is generally acute monoarthritis especially in the larger joints of the lower extremities, healing without a sequelae. However some of the patients develop different type of chronic arthritis, predominantly oligoarticular juvenile idiopathic arthritis (JIA) and juvenile pondyloarthropathies (JSpA). Studies on JSpA among childhood FMF patients are spare.ObjectivesTo evaluate frequency of JSpA in a large childhood FMF cohort. Furthermore, we aimed to define main characteristics of JSpA among childhood FMF patients.MethodsA total of 320 juvenile FMF patients were blindly questioned according to recently proposed criteria for JSpA by 3 researchers (EO, DS, ET) that were previously educated for FMF and JSpA. A standardised case report form was prepared and completed for each patient. This form was including demographic data, clinical features, MEFV mutation and treatment. Patients fulfilled the JSpA criteria and were classified as probable JSpA. Afterwards, an expert in paediatric rheumatology (OK) reevaluated the classified patients and some of them were confirmed to be a definite while some of them were accepted as potential JSpA patients.ResultsAs a result, 37 patients (11.5%) were initially classified as potential JSpA. Furthermore, 32 (10%) of them were accepted as definite and 5 (1.5%) patients as probable JSpA in childhood FMF. Demographic, clinical and treatment data of definitive JSPA patients are shown in Table I. The most frequent MEFV mutation among JSPA patients was M694V (63.33%).Table I. Demographic, clinical and genetic features of childhood FMF patients.FMF +Definite JSPAFMF +Probable JSPAFMF patients without JIA and JSpAFMF+JIA (except ERA or JSpA)
Patients, n32526815Female, n (%)10 (31.25%)1 (20%)148 (55.22%)10 (66.66%)Age of disease onset, mean±SD years7.19±3.685.60±4.934.91±3.404.93±3.32Age at study, mean±SD years14.84±3.7013.40±1.6712.51±4.4310.73±3.57Family History of FMF, n (%)15 (46.87%)1 (20%)132 (49.25%)6 (40%)Colchicine resistance in FMF patients, n(%)2 (6.25%)014 (5.22%)1 (6.66%)M694V mutation n(%)Homozygote, n(%)Heterozygote, n(%)Compound heterozygote, n(%)NA, n(%)19/30 (63.33%)7 (36.84%)5 (26.31%)7 (36.84%)2 (6.25%)3 (60%)2 (66.66%)1 (33.33%)00148/245 (60.40%)51 (34.45%)54 (36.48%)43 (29.05%)23 (8.58%)11 (73.33%)8 (72.72%)2 (18.18%)1 (9.09%)0Disease onset over 6 years,n (%) years26 (81.25%)5 (100%)6 (40%)Oligorthritis, n(%)21 (65.62%)1 (20%)14 (93.33%)Inflammatory back pain, n(%)17/32 (53.12%)3/5 (60%)0Enthesopathy22/32 (68.75%)3/5 (60%)0Sacroiliitis14/21 (66.66%)0/1 (0)0/5 (0)ConclusionsArticular involvement compatible with JSpA could be seen in childhood FMF patients. Spondyloarthropathy was detected in 10% of childhood FMF cases. The M694V mutation is the most common MEFV mutation among JSpA patients with FMF. JSpA should be considered in childhood FMF patients, especially in those chr...